Frost & Sullivan Lauds Micronoma with Award for Technology Innovation Leadership

Frost & Sullivan Lauds Micronoma with Award for Technology Innovation Leadership

Frost & Sullivan Lauds Micronoma with Award for Technology Innovation Leadership

Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifying the “infinite potential” of using microbiome markers to diagnose cancer.

SAN DIEGO–(BUSINESS WIRE)–Based on an independent team of experts’ rigorous evaluation of a broad field of nominated companies, Frost & Sullivan has selected Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, to receive this year’s Best Practices Technology Innovation Leadership Award in the North America liquid biopsy for lung cancer market.

“Driving innovation and growth is a difficult task made even harder by the strategic imperatives forcing change today, such as disruptive technologies, value chain compression, and industry convergence,” Frost & Sullivan said. “In this context, Micronoma’s recognition signifies an even greater accomplishment.”

Noting that lung cancer has one of the highest mortality rates, the panel concluded that Micronoma’s Oncobiota™ platform delivers improved diagnostic capabilities that can result in better patient outcomes and lower costs. OncobiotaLUNG was recently granted FDA Breakthrough Designation Devices status.

Frost & Sullivan, a research-based think tank focused on supporting the public and private sectors on their journey to visionary innovation, credited Micronoma for distinguishing itself compared to competitors based on performance in numerous technology and business best practice categories, including commitment to innovation, creativity and growth potential in a rapidly expanding market.

“We’re extremely gratified to receive this award that recognizes the revolutionary advances Micronoma is making in early cancer detection,” Sandrine Miller-Montgomery, Micronoma CEO and co-founder, said. “Our unwavering commitment to offering a minimally invasive diagnostic option to clinicians and patients, starting with lung cancer, should be ready for clinicians this year. Our technology has vast potential to reduce the need for costly and sometimes dangerous tissue biopsies and, most importantly, help patients lead longer lives.”

To learn more about Micronoma, please go to

About Micronoma

Micronoma is the first cancer-detection company utilizing signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma was founded in 2019 by leaders in microbiome research with the goal of advancing early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are met by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company is headquartered in San Diego, California.


Celia Sepulveda
Corporate Communications Director
(858) 337-1326